Publications by authors named "V J Moebus"
The development of balanced, healthy, ready-to-consume, and easy-to-prepare products has led to the development of new food technologies. Despite their high commercial value, bullfrog () carcasses result in low yields, with the thighs being the most marketed in comparison to other carcass portions. In this sense, liver pâté is a traditional food consumed worldwide, mainly in European countries, and may be prepared by incorporating bullfrog meat by-products and certain viscera.
View Article and Find Full Text PDFArticle Synopsis
- A study investigated the long-term survival benefits of adding lapatinib to chemotherapy and trastuzumab in HER2-positive early breast cancer, comparing rates of pathological complete response (pCR).* -
- Over a ten-year follow-up, patients receiving the combination treatment showed event-free survival (EFS) rates of 67% and overall survival (OS) rates of 80%, with pCR linked to significantly better EFS and OS.* -
- The findings indicate that neoadjuvant anti-HER2 therapy provides lasting survival advantages for patients, particularly for those achieving pCR, without any new safety issues reported.*
Background: In HER2-positive breast cancer, time elapsed between completion of (neo)adjuvant trastuzumab and diagnosis of metastatic disease ('trastuzumab-free interval', TFI) is crucial to choose the optimal first-line treatment. Nevertheless, there is no clear evidence to support its possible prognostic role.
Methods: In the Adjuvant Lapatinib and/or Trastuzumab Treatment Optimisation (ALTTO) trial, patients with HER2-positive early breast cancer were randomised to 1 year of either trastuzumab alone, lapatinib alone, their sequence or their combination.
Background: Dose-dense (DD) adjuvant chemotherapy improves outcomes in early breast cancer (BC). However, there are no phase 3 randomized data to inform on its combination with trastuzumab for patients with human epidermal growth factor receptor 2 (HER2)-positive disease.
Methods: This was a protocol-predefined secondary analysis of the randomized phase 3 Pan-European Tailored Chemotherapy (PANTHER) trial.